Carna Biosciences, Inc.
Supplementary Explanation Document on Fundraising
To advance clinical development of docirbrutinib and monzosertib, Carna Biosciences, Inc. will carry out a 561 million yen convertible bond with warrants issuance and an 850 million yen equity issuance. Proceeds will be allocated to clinical development, preclinical work, and working capital, and the structure spreads dilution.
Key Figures
- Convertible bond with warrants issuance proceeds: 561 million yen
- Equity issuance proceeds: 850 million yen
- Issuance costs (deduction): -42 million yen
AI要約
Overview of Fundraising
Carna Biosciences, Inc. is conducting this fundraising to reliably advance the clinical development of docirbrutinib (AS-1763) and monzosertib (AS-0141), enhance pipeline value, and maintain funding levels. By combining a convertible bond with warrants issuance and an equity issuance, the company secures a substantial amount of funds while dispersing dilution.
Use of Proceeds and Breakdown of Fundraising
Proceeds will be used for clinical development costs for docirbrutinib and monzosertib, preclinical pipeline development costs, and working capital. Through allocations for the 4th to 6th tranches, a total of approximately 1,369 million yen is planned to be raised. Allottees include Cantor Fitzgerald Europe and others.
Carna Biosciences, Inc.
Company overview · Stock price · Financial data · All IR
